FDA Submission Status Update for ANDA220055 by MSN Laboratories
MSN Laboratories has submitted ANDA220055 with a standard review priority.
Published: July 19, 2026
Updated: July 19, 2026
Author: Humanexa Intelligence
Therapeutic area: Not specified
Company: MSN Laboratories
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Company
MSN Laboratories
Signal assessment
Signal strength
moderate
Confidence level
moderate
Signalmoderate
Confidencemoderate
Why it matters
The submission of ANDA220055 by MSN Laboratories represents a significant step in the generic drug market, which could alter competitive dynamics. Monitoring this application is crucial for understanding potential impacts on pricing and market share within the relevant therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Follow up on the review timeline and any potential approval outcomes for ANDA220055.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.